Findings

What do systematic reviews say?

12 questions · 13 findings · 3 reviews · ENT

Sort:Best matchNewest Highest certainty Download CSV

No studies found 5 · 38.5%GRADE not reported 0 · 0%Very low 1 · 7.7%Low 3 · 23.1%Moderate 3 · 23.1%High 1 · 7.7%

Topical antibiotics with steroids vs topical antibiotics

Health‐related quality of life · people (of any age) with chronic suppurative otitis media or ear discharge

The review found no eligible studies for this question.

2 findings from 1 review

Topical antibiotics with steroids for chronic suppurative otitis media 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Topical antibiotics with steroids for chronic suppurative otitis media 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intranasal steroid spray vs no treatment

Disease‐specific quality of life · children aged 6 months to 12 years with otitis media with effusion (OME)

The review found no eligible studies for this question.

1 finding from 1 review

Topical and oral steroids for otitis media with effusion (OME) in children 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Topical antibiotics with steroids vs placebo/no treatment

Health‐related quality of life · chronic suppurative otitis media

The review found no eligible studies for this question.

1 finding from 1 review

Topical antibiotics with steroids for chronic suppurative otitis media 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intranasal steroid spray vs placebo

Disease‐specific quality of life · children aged 6 months to 12 years with otitis media with effusion (OME)

1 finding from 1 review

Topical and oral steroids for otitis media with effusion (OME) in children 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Oral steroids vs no treatment

Disease‐specific quality of life · children aged 6 months to 12 years with otitis media with effusion (OME)

The review found no eligible studies for this question.

1 finding from 1 review

Topical and oral steroids for otitis media with effusion (OME) in children 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral steroids vs placebo

Disease‐specific quality of life · children aged 6 months to 12 years with otitis media with effusion (OME)

1 finding from 1 review

Topical and oral steroids for otitis media with effusion (OME) in children 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)

Generic quality of life measures · patients with chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 38 participants
Very low

Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)

Disease‐specific quality of life · patients with severe chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 784 participants
High

Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)

Disease‐specific quality of life · patients with chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 265 participants
Moderate

Anti‐IL‐5 mAb (mepolizumab) vs placebo (on top of topical steroids)

Disease‐specific quality of life · patients with severe chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 105 participants
Low

Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)

Generic quality of life measures · patients with severe chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 766 participants
Moderate

Anti‐IL‐5 mAb (mepolizumab) vs placebo (on top of topical steroids)

Generic quality of life measures · patients with severe chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 105 participants
Low